Galera Therapeutics

Galera Therapeutics, Inc. operates as a clinical-stage biotechnology company. It focuses on developing and commercializing a pipeline of novel, proprietary therapeutics for cancer. The firm is involved in the prevention of radiation-induced toxicity, including mucositis and the treatment of fibrosis and cancer. Its product candidate, GC4419, reduces severe oral mucositis in patients with head and neck cancer undergoing radiation therapy and receiving cisplatin, a chemotherapy drug. The company was founded by Robert A. Beardsley, Randy W. Weiss, and Dennis P. Riley in 2009 and is headquartered in Malvern, PA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Galera Therapeutics, Inc. is a clinical stage biotechnology company, which engages in developing and commercializing a pipeline of novel, proprietary therapeutics for cancer. It is also involved in the prevention of radiation-induced toxicity, including mucositis and the treatment of fibrosis, and cancer. The company was founded by Robert A. Beardsley, Randy W. Weiss, and Dennis P. Riley in 2009 and is headquartered in Malvern, PA.

NDA based on two positive randomized, double-blinded, placebo-controlled trials which enrolled a total of 678 patients NDA based on two positive randomized, double-blinded, placebo-controlled trials which enrolled a total of 678 patients

Galera Submits New Drug Application for Avasopasem for Severe Oral Mucositis

MALVERN, Pa., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will present at the Piper Sandler 34th Annual Healthcare Conference on Tuesday, November 29, 2022 at 11:10 a.m. E.T.

Galera to Present at Piper Sandler Annual Healthcare Conference

Company on track to submit NDA to U.S. FDA for avasopasem by end of 2022

Galera Reports Third Quarter 2022 Financial Results and Recent Corporate Updates

Tumor outcomes and overall survival maintained in patients with HNC at one-year

Galera Announces Presentation of Phase 3 ROMAN Long-term Follow-up Data at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting

MALVERN, Pa., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that tumor outcomes data from its Phase 3 ROMAN trial of avasopasem for severe oral mucositis (SOM) and final data from its Phase 2 AESOP trial of avasopasem for chemoradiotherapy-induced esophagitis will be highlighted in two presentations at the upcoming 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting, taking place October 23-26, 2022 in San Antonio, Texas. Additionally, poster presentations will highlight the Phase 2 EUSOM trial of avasopasem for SOM in Europe and the ongoing GRECO-1 trial of rucosopasem for non-small cell lung cancer.

Galera to Present at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting

MALVERN, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12, 2022 at 4:30 p.m. E.T.

Galera to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

MALVERN, Pa., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced the appointment of Eugene P. Kennedy, M.D., F.A.C.S., as Chief Medical Officer (CMO). Dr. Kennedy is a renowned Johns Hopkins-trained surgical oncologist and former Chief of Pancreatic and Hepatobiliary Surgery at Thomas Jefferson University with over 15 years' experience in clinical development and biopharma leadership. He will succeed Jon T. Holmlund, M.D., who will retire at the end of this year. In the interim, Dr. Kennedy and Dr. Holmlund will work together closely to ensure a smooth and successful transition, with particular focus on the preparation for the Company's submission of an NDA to the U.S. FDA for avasopasem by the end of 2022.

Galera Appoints Eugene P. Kennedy, M.D.

Galera Reports Second Quarter 2022 Financial Results and Recent Corporate Updates

Galera Therapeutics Inc (NASDAQ: GRTX) announced results from the open-label Phase 1 stage of the GRECO-1 trial of rucosopasem in combination with stereotactic body radiation therapy (SBRT) for non-small cell lung cancer (NSCLC).  Enrollment is ongoing in the randomized, double.

Galera Therapeutics' Rucosopasem Shows Early Anti-Cancer Activity, Pulmonary Function Preservation

Galera Announces Results from Phase 1 Stage of GRECO-1 Trial of Rucosopasem with SBRT for NSCLC

MALVERN, Pa., June 02, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will present at the 2022 Jefferies Healthcare Conference on Thursday, June 9, 2022 at 2:00 p.m. E.T.

Galera to Present at Jefferies Healthcare Conference

Avasopasem produced clinically meaningful, statistically significant reduction of severe oral mucositis (SOM) in patients with locally advanced head and neck cancer receiving radiotherapy

Galera Announces Oral Presentation at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Detailing Results from Phase 3 ROMAN Trial of Avasopasem

Company plans to submit a New Drug Application (NDA) for avasopasem for the treatment of radiotherapy-induced severe oral mucositis (SOM) by end of 2022

Galera Reports First Quarter 2022 Financial Results and Recent Corporate Updates

After discussions with FDA, Company is on track to file an NDA for avasopasem for the treatment of radiotherapy-induced severe oral mucositis by end of 2022 After discussions with FDA, Company is on track to file an NDA for avasopasem for the treatment of radiotherapy-induced severe oral mucositis by end of 2022

Galera Announces Plan to Submit Avasopasem NDA by Year End

Galera Therapeutics Inc (NASDAQ: GRTX) announced topline results from Phase 2a AESOP trial of avasopasem for severe acute radiation-induced esophagitis in lung cancer patients receiving concurrent chemoradiotherapy. Esophagitis is an early side effect of radiation or chemoradiation.

Galera Posts Topline Data From Avasopasem Study In Chemoradiotherapy-Induced Esophagitis

MALVERN, Pa., April 27, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that clinical data from its Phase 3 ROMAN trial of avasopasem for severe oral mucositis will be presented in an oral presentation at the upcoming 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 3-7, 2022 in Chicago, Illinois.

Galera to Present at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Galera Therapeutics is developing drugs that reduce side effects from anti-cancer radiotherapy and improve the treatment outcome.

Is Galera Therapeutics Stock A Buy, Sell, Or Hold? Several Catalysts To Watch In 2022

Positive Phase 3 ROMAN trial of avasopasem for severe oral mucositis met primary and secondary endpoint; Company intends to meet with FDA in 2022 about NDA submission

Galera Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Updates

MALVERN, Pa., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will present at the H.C. Wainwright BioConnect Conference, taking place January 10-13, 2022.

Galera to Present at H.C. Wainwright BioConnect Conference

Kosmos Energy

Transocean

Which penny stocks are you buying right now? The post Top Penny Stocks to Buy in 2022?

Top Penny Stocks to Buy in 2022? Check These 3 Out Right Now

Jaguar Health

Petros Pharmaceuticals

Which penny stocks are you watching right now? The post Trending Penny Stocks to Buy Today?

Trending Penny Stocks to Buy Today? 3 For Your Watchlist

Citi has raised the price target on Galera Therapeutics Inc (NASDAQ:GRTX) to $20 (suggesting 361% upside) from $11 and maintained a Buy rating.  Analyst Yigal Nochomovitz is re-introducing avasopasem with a 90% probability of success into his revenue model following the recent "stunning" disclosure that Galera discovered an error in their computer code used to compute the statistical significance of the primary endpoint in the ROMAN Phase 3 trial.

Galera Therapeutics Shares Surge As Citi Bumps Up Price Target To $20

Vinco Ventures

Fortuna Silver Mines

Which penny stocks are you watching as 2021 comes to an end? The post Check These Penny Stocks Out For Your Watchlist As the Market Dips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Check These Penny Stocks Out For Your Watchlist As the Market Dips

Investors need to pay close attention to Galera (GRTX) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Galera (GRTX) Stock?

CPS Technologies

Color Star Technology

Wondering how to trade penny stocks and which could be worth watching? The post Penny Stocks Are Volatile, Here's How to Trade Them and 3 to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

News for Galera Therapeutics Stock (GRTX)